Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Envestnet Asset Management Inc.

Key Points

• Envestnet Asset Management reduced its Vertex Pharmaceuticals stake by 3.2%, selling 15,937 shares and retaining 487,627 shares valued at approximately $242.2 million. Institutional investors collectively own 90.96% of VRTX.
• Vertex insiders also reported sales under pre-arranged Rule 10b5-1 plans: executives Ourania Tatsis and Duncan McKechnie sold shares worth about $787,000 and $800,000, respectively.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and $573.83 price target. Vertex’s latest revenue rose 12.5% year over year to $3.33 billion, though quarterly EPS narrowly missed estimates.

Envestnet Asset Management Inc. cut its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 3.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 487,627 shares of the pharmaceutical company's stock after selling 15,937 shares during the period. Envestnet Asset Management Inc. owned 0.19% of Vertex Pharmaceuticals worth $242,219,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in VRTX. Community Financial Services Group LLC purchased a new position in shares of Vertex Pharmaceuticals during the 2nd quarter valued at approximately $26,000. Meeder Asset Management Inc. purchased a new position in Vertex Pharmaceuticals in the 2nd quarter valued at about $26,000. Elevation Wealth Partners LLC boosted its holdings in Vertex Pharmaceuticals by 103.7% in the 2nd quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 28 shares during the last quarter. Pingora Partners LLC purchased a new stake in Vertex Pharmaceuticals during the 2nd quarter worth approximately $32,000. Finally, City Holding Co. increased its stake in Vertex Pharmaceuticals by 128.1% during the 2nd quarter. City Holding Co. now owns 73 shares of the pharmaceutical company's stock worth $36,000 after buying an additional 41 shares in the last quarter. Hedge funds and other institutional investors own 90.96% of the company's stock.

Insider Activity at Vertex Pharmaceuticals

In related news, EVP Ourania Tatsis sold 1,500 shares of the company's stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $524.99, for a total value of $787,485.00. Following the transaction, the executive vice president directly owned 45,321 shares in the company, valued at approximately $23,793,071.79. This represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Duncan McKechnie sold 1,541 shares of the stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $519.00, for a total value of $799,779.00. Following the completion of the transaction, the executive vice president owned 11,001 shares of the company's stock, valued at $5,709,519. The trade was a 12.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.20% of the company's stock.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Positive Phase 2 data for inaxaplin strengthened confidence in Vertex’s kidney-disease strategy. The company reported encouraging AMPLIFIED trial results, completed enrollment in the AMPLITUDE study and expects interim data in early 2027. Vertex Posts Positive Phase II Data on Kidney Disease Drug
• Positive Sentiment: Analyst support improved. TD Cowen raised its price target for VRTX to $550 from $525 while maintaining a Buy rating, signaling greater confidence in Vertex’s growth prospects and pipeline potential. TD Cowen Adjusts Price Target on Vertex Pharmaceuticals
• Positive Sentiment: Pipeline diversification is attracting investor interest. Povetacicept and inaxaplin could provide new growth engines in kidney disease, reducing Vertex’s long-term reliance on its cystic-fibrosis business. One analysis also argued that the stock may be undervalued based on future cash-flow potential. Will Vertex’s Kidney Disease Pipeline Be a New Growth Engine?
• Neutral Sentiment: Canaccord Genuity initiated or reiterated a Hold rating, indicating a balanced view of Vertex’s valuation and near-term upside despite the promising pipeline. Vertex Gets a Hold from Canaccord Genuity
• Neutral Sentiment: Reported short interest of zero shares suggests no measurable short-selling pressure, although the figure may reflect a reporting or data issue rather than a meaningful change in investor positioning.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on VRTX shares. Leerink Partners initiated coverage on Vertex Pharmaceuticals in a research note on Monday. They issued an "outperform" rating and a $594.00 price objective for the company. Canaccord Genuity Group boosted their price target on shares of Vertex Pharmaceuticals from $436.00 to $442.00 and gave the stock a "hold" rating in a research report on Tuesday, August 4th. Weiss Ratings raised shares of Vertex Pharmaceuticals from a "buy (b-)" rating to a "buy (b)" rating in a research note on Thursday, September 10th. JPMorgan Chase & Co. reiterated an "overweight" rating and issued a $560.00 price objective (up from $515.00) on shares of Vertex Pharmaceuticals in a report on Friday, September 11th. Finally, TD Cowen raised their target price on shares of Vertex Pharmaceuticals from $525.00 to $550.00 and gave the stock a "buy" rating in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $573.83.

Vertex Pharmaceuticals Trading Up 1.2%

Shares of VRTX stock opened at $522.38 on Friday. The company's 50-day moving average price is $514.71 and its 200-day moving average price is $475.45. The stock has a market cap of $132.58 billion, a price-to-earnings ratio of 30.41, a PEG ratio of 2.26 and a beta of 0.32. Vertex Pharmaceuticals Incorporated has a twelve month low of $377.02 and a twelve month high of $560.25.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.74 by ($0.01). Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%.The firm had revenue of $3.33 billion for the quarter, compared to analyst estimates of $3.23 billion. During the same quarter in the previous year, the business posted $4.52 earnings per share. Vertex Pharmaceuticals's revenue for the quarter was up 12.5% on a year-over-year basis. As a group, equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 16.69 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company combines research in human genetics with drug discovery and development.

Vertex is best known for its cystic fibrosis portfolio, which includes CFTR modulator therapies such as Kalydeco, Orkambi, Symdeko and the combination marketed as Trikafta in the United States and Kaftrio in other markets.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.